US Stock MarketDetailed Quotes
TSVT 2seventy bio
- 3.255
- -0.085-2.54%
Trading Dec 13 12:09 ET
167.92MMarket Cap-1.78P/E (TTM)
3.370High3.170Low128.57KVolume3.310Open3.340Pre Close415.64KTurnover0.29%Turnover RatioLossP/E (Static)51.59MShares6.40052wk High0.74P/B143.67MFloat Cap2.89552wk Low--Dividend TTM44.14MShs Float64.000Historical High--Div YieldTTM5.99%Amplitude1.535Historical Low3.232Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
2seventy bio Stock Forum
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, wi...
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...
No comment yet